Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01441869 · ClinicalTrials.gov registry record · Phase 1
Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin Produc
A Phase 1 study of Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT01441869 is a Phase 1 study of Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin that has completed, run by AstraZeneca. The registered enrollment target is 28 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01441869, a Phase 1 study of Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
Study in healthy subjects to measure amount of drug in blood after dosing with different saxagliptin / metformin products.
Conditions Studied
Interventions
- DRUG Onglyza (saxagliptin)
- DRUG Diabex
- DRUG 5-mg saxagliptin/1000 mg metformin
- DRUG 5-mg saxagliptin/500 mg metformin
Study Locations (1)
Kansas
- Research Site - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2011-10 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01441869
The ClinicalTrials.gov registry entry for NCT01441869 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin appearing as the primary indexed condition, and to 4 interventions - of which Onglyza (saxagliptin) is the first listed.
NCT01441869 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT01441869 about?
NCT01441869 is a clinical study titled "Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin Produc". Study in healthy subjects to measure amount of drug in blood after dosing with different saxagliptin / metformin products.
What is the current status of trial NCT01441869?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2011-10. Estimated completion is 2011-12.
What conditions does trial NCT01441869 study?
This clinical trial studies the following conditions: Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin.
What interventions are being tested in trial NCT01441869?
The interventions under investigation include: Onglyza (saxagliptin) (DRUG), Diabex (DRUG), 5-mg saxagliptin/1000 mg metformin (DRUG), 5-mg saxagliptin/500 mg metformin (DRUG).
Who is sponsoring clinical trial NCT01441869?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01441869 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.